Evolus upgraded by Barclays with a new price target
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/17/2025 | $21.00 | Buy | BTIG Research |
| 1/29/2024 | $10.00 → $16.00 | Equal Weight → Overweight | Barclays |
| 6/23/2022 | $18.00 | Buy | Needham |
| 5/12/2022 | $8.00 → $10.00 | Underweight → Equal Weight | Barclays |
| 1/20/2022 | $11.00 | Hold → Buy | Truist |
| 11/3/2021 | $22.00 → $15.00 | Buy | HC Wainwright & Co. |